Significance of Transmission Electron Microscopy in Subtyping of Monocytic Leukemia

Yong-Xin Ru, MD, Yin-Chang Mi, MD, Jin-Hua Liu, BSc, Hui-Jun Wang, MD, Shi-Xuan Zhao, BSc, Wen Cui, BSc, Cheng-Wen Li, BSc, Qing-Hua Li, MD, Xiao-Fan Zhu, MD, Zhi-Jian Xiao, MD, Jian-Xiang Pang, MD, and Jian-Xiang Wang, MD

Institute of Hematology & Blood Diseases Hospital,
State Key Laboratory of Experimental Hematology,
Chinese Academy of Medical Sciences and
Peking Union Medical College, Tianjin, China

ABSTRACT

The objective of this paper is to produce an ultrastructural classification of acute monocytic leukemia (AML-M5) in relation to clinical behaviors. The ultrastructural characteristics of blasts of the monocytic series were analyzed in 72 M5 patients by transmission electron microscopy (TEM), in terms of their content of typical monoblasts, atypical monoblasts, atypical promonocytes, and typical promonocytes in bone-marrow aspirates. Four kinds of monocytic blasts were identified by cell size and shape, nuclear profile, nucleocytoplasmic ratio, heterochromatin content, nucleolus, granules, vesicles, and Golgi apparatus. Their characteristics of remission rate, cytochemistry, immunophenotype, and cytogenetics were also investigated. The data obtained permitted M5 patients to be divided into monoblast and promonocyte types. Monoblast-type patients expressed weaker monocytic enzymograms and specific antigen staining for CD14 and CD64, compared with promonocyte-type patients. Monoblast patients had higher CR than promonocyte patients. Therefore, TEM subclassification of patients differs from and improves upon the light microscopical criteria for distinguishing monoblasts and promonocytes and has clinical significance.

Keywords: acute monocytic leukemia, classification, differentiation, ultrastructure

The development or maturation of monocytes in the bone marrow is a dynamic process, including myeloid progenitor, monoblast, promonocyte, and monocyte stages. Circulating monocytes and various histiocytes are also recognized according to their location and function in peripheral blood and tissues. In acute monocytic leukemia (M5), monoblasts, promonocytes, and monocytes are distinguished by light microscopy, and M5 is further subdivided into M5a and M5b by the percentage of blast types in the French-American-British (FAB) and World Health Organization (WHO) classifications [1, 2].

M5 has distinct characteristics compared with other AML subtypes in terms of immunophenotype, karyotype, and genetics. CD14, CD56, and CD64 are expressed in M5 in addition to common myeloid antigens, and the 11q23 translocation occurs more frequently in M5 than in other AML subtypes [3]. The FMS-like tyrosine kinase 3 (FLT3) mutation is also frequently found in M5 [4].

Received 15 December 2008; accepted 5 January 2009.

Address correspondence to Dr. Yong-Xin Ru, MD, Department of Electron Microscopy, Institute of Hematology & Blood Diseases Hospital, Peking Union Medical College, Nanjing Lu 288, Tianjin 300020, China. E-mail: ruyongxin@126.com

We thank Brian Eyden (Christie NHS Foundation Trust, Manchester, UK), for linguistic revision of the manuscript. We also thank the hematologists in our hospital for providing the cases studied.
The characteristic immunophenotype, genetics, and prognostic factors for M5a and M5b have been compared recently. Haferlach et al. [4] detected an aberrant karyotype in 75.9% of M5a and 28.8% of M5b, of which 11q23/MLL aberrations were found in 31% of M5a and 12.1% of M5b. These data suggest that M5 should be categorized as two different groups [5]. Other clinical investigations indicated more aberrant karyotype and less FLT3 mutation in M5a compared with M5b [6]. In contrast, some studies showed no significant differences in immunophenotype, karyotype, or prognosis between M5a and M5b [7, 8].

Figure 1. (A) Typical monoblast with diameter of 10 μm, high NCR, rounded nuclear contour, smaller nucleolus (arrow), increased heterochromatin (short arrow), scarce cytoplasm, and few organelles. ×10,000. (B) Nuclear membrane positive for MPO and no positively stained granules in the cytoplasm. ×10,000. (C, D) TMB subtype. ×4000, ×3500.
We suppose this controversy might result from uncertainties in the morphological (light microscopical) distinction of monoblasts from promonocytes. Since there are no strict criteria to distinguish monoblasts from promonocytes cytochemically, immunophenotypically, and cytogenetically, it may be necessary to introduce transmission electron microscopy (TEM) to distinguish blasts in M5, and this is the objective of the present study.

**MATERIALS AND METHODS**

**Patients and FAB/WHO Diagnostic Criteria**

Seventy-two patients with de novo M5 were accessions of the Blood Diseases Hospital from 2004 to 2006. The diagnosis was established by conventional criteria, combining results from clinical features, flow cytometry, cytochemistry, and cytogenetics. M5a and M5b were subtyped, with all patients fulfilling the following criteria: (1) At least 80% of the leukemic cells were morphologically of monocytic lineage, and included monoblasts, promonocytes, and monocytes. (2) A minor granulocytic component was present (<20%). (3) In M5a, the majority of the monocytic series were monoblasts (≥80%), while in M5b, the majority were promonocytes (≥80%). (4) The leukemic population usually showed intense nonspecific esterase activity with sodium fluoride (NaF) inhibition. (5) Patients had ≥20% bone-marrow leukemic cells. The cases that were difficult to classify were designated as M5u. Fifty-four of the 72 patients accepted standard chemotherapy.

**TEM Technique and Classification**

The procedure for morphological TEM was as previously described [9]. Myeloperoxidase activity (MPO) was detected by the method of Roels et al. [10]. MPO-positivity was assessed in 200 blasts from each specimen, and calculated as a percentage. Four kinds of monocytic blast were ultrastructurally defined as follows. (1) *Typical monoblast* (TMB): small size, round shape, round nucleus, high nucleocytoplasmic ratio (NCR), prominent heterochromatin, small nucleolus, few cytoplasmic organelles such as granules or vesicles, and rare Golgi apparatus (Figure 1). (2) *Atypical monoblast* (AMB): larger size, only slightly irregular shape, large nucleus, prominent nucleolus, high NCR, reduced heterochromatin, and moderate amount of cytoplasm containing fewer cytoplasmic organelles (Figure 2A, B). (3) *Atypical promonocyte* (APM): shape and nuclear structure as in AMB, rich in granules and vesicles and immature Golgi apparatus (Figure 2C, D). (4) *Typical promonocyte* (TPM): irregular shape, cell-surface processes, voluminous cytoplasm containing plentiful granules and vesicles and fully developed Golgi apparatus, lower NCR, irregular nucleus with increased heterochromatin and small or obscure nucleolus, occasional vacuoles or phagocytosis (Figure 3, Table 1). Patients were subtyped on the basis of the predominant TMB, AMB, APM, or TPM.

**Karyotyping**

Chromosome analysis was performed on short-term bone-marrow cultures by standard methods with at least 20 mitoses analyzed in each case.

**Cytochemistry**

Cytochemistry for peroxidase (POX), Sudan black B (SBB), periodic acid–Schiff (PAS), naphthol AS-D chloracetate esterase (CE), acid phosphatase (ACP), α-naphthyl butyrate esterase (NBE), α-naphthyl acetate esterase (NAE), and their inhibition by NaF (NAE + NaF) were performed according to routine procedures. The scoring was that of the International Committee for Standardization in Hematology [11].

**Immunophenotyping**

Immunophenotype was analyzed on a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA) equipped with Cellquest software [12]. Cytoplasmic and nuclear antigens were detected with FACS permeabilization solution (Becton Dickinson). Antigens detected were lymphoid markers CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, CD22, and CD79a; myeloid markers CD13, CD14, CD16, CD33, CD64, CD117, and MPO. The nonspecific markers CD34, CD56, and HLA-DR were also detected. Positivity was defined as expression in ≥20% of blasts for surface antigens and ≥10% of blasts for cytoplasmic and nuclear antigens.

**Statistical Analyses**

Age, sex, abnormal karyotype, complete remission, and immunophenotype were compared with chi-square test, respectively, and cytochemical characteristics using Variance Test in SPSS. MB (TMB + AMB) and PM (TPM + APM) types were also compared.

**RESULTS**

**Patients**

The 72 patients consisted of M5a (n = 10), M5b (n = 51), and M5u (n = 11). The median age for all patients was 37 years (range, 2–67); 34 years (range,
Figure 2. (A) Atypical monoblast, 15 μm in diameter, less heterochromatin, prominent nucleolus, moderate cytoplasm containing fewer organelles. × 5000. (B) AMB subtype. × 4000. (C) Atypical promonocyte, with a size and nuclear features like those of atypical monoblasts, but rich in granules, vesicles, and Golgi apparatus. × 6000. (D) APM subtype. × 3000.

12–54) for M5a, 38 years (range, 6–67) for M5b, and 41 years (range, 2–63) for M5u. Karyotyping was tested in 6 of 9 M5a patients (66%), 17 of 44 M5b (36%), and 3 of 6 M5u (50%). Complete remission (CR) was achieved
in 4 of 7 M5a patients (57%), 24 of 41 M5b (58%), and 3 of 6 M5u (50%). There were no statistical differences in age, sex, karyotype abnormality, or CR between M5a and M5b patients.

Figure 3. Typical promonocyte and TPM subtype. (A) Blasts showing irregular shape, 16 μm in diameter, many processes, lower NCR, twisted nucleus with more heterochromatin and obscure nucleolus, prominent cytoplasm containing many small granules and vesicles. ×4000. (B) Blasts containing highly developed Golgi apparatus. ×20,000. (C) Blasts showing erythrophagocytosis. ×3000. (D) Blasts showing active features such as vacuolization and phagocytosis and longer processes. ×3500.
TEM Subtyping of Monocytic Leukemia

Table 1. Ultrastructural characteristics of the four subtypes of the monocytic series in AML-M5.

<table>
<thead>
<tr>
<th>Feature</th>
<th>TMB</th>
<th>AMB</th>
<th>APM</th>
<th>TPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shape</td>
<td>Round</td>
<td>Round or elliptical</td>
<td>Irregular</td>
<td>Irregular</td>
</tr>
<tr>
<td>Surface</td>
<td>Smooth</td>
<td>Rounded processes</td>
<td>Less processes</td>
<td>More Slender processes</td>
</tr>
<tr>
<td>Diameter</td>
<td>≤11 µm</td>
<td>≥12 µm</td>
<td>≥12 µm</td>
<td>≥12 µm</td>
</tr>
<tr>
<td>NCR</td>
<td>≥1:1.2</td>
<td>≥1:1.5</td>
<td>≥1:1.5</td>
<td>≤1:2</td>
</tr>
<tr>
<td>Nucleus</td>
<td>Regular</td>
<td>Slightly irregular</td>
<td>Slightly irregular</td>
<td>Irregular</td>
</tr>
<tr>
<td>Nucleolus</td>
<td>≤3 µm</td>
<td>≥3 µm</td>
<td>≥3 µm</td>
<td>≤3 µm</td>
</tr>
<tr>
<td>Heterochromatin</td>
<td>Increased</td>
<td>Decreased</td>
<td>Decreased</td>
<td>Increased</td>
</tr>
<tr>
<td>Granules (number)</td>
<td>Few</td>
<td>Few</td>
<td>Moderate</td>
<td>Many</td>
</tr>
<tr>
<td>Ga Development</td>
<td>Little</td>
<td>Little</td>
<td>Moderate</td>
<td>Many</td>
</tr>
<tr>
<td>Vesicles</td>
<td>Few</td>
<td>Few</td>
<td>Moderate number</td>
<td>Many</td>
</tr>
<tr>
<td>Vacuoles</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>Phagocytosis</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
<td>Occasional</td>
</tr>
</tbody>
</table>

Note: NCR, nuclear-cytoplasm ratio; GA, Golgi apparatus.

Table 2. Clinical data of the four ultrastructural subtypes of AML-M5.

<table>
<thead>
<tr>
<th>UST</th>
<th>Cases</th>
<th>MA</th>
<th>Sex (F/M)</th>
<th>KA/CT (%)</th>
<th>CR/TC (%)</th>
<th>M5a</th>
<th>M5b</th>
<th>M5u</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMB</td>
<td>13</td>
<td>39</td>
<td>8/5</td>
<td>5/10 (50)</td>
<td>3/9 (33)</td>
<td>3</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>AMB</td>
<td>21</td>
<td>43</td>
<td>5/16</td>
<td>8/17 (47)</td>
<td>6/15 (40)</td>
<td>5</td>
<td>12</td>
<td>4</td>
</tr>
<tr>
<td>APM</td>
<td>14</td>
<td>35</td>
<td>7/7</td>
<td>8/13 (62)</td>
<td>8/12 (67)</td>
<td>1</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>TPM</td>
<td>24</td>
<td>34</td>
<td>6/18</td>
<td>5/19 (28)</td>
<td>13/18 (72)</td>
<td>1</td>
<td>20</td>
<td>3</td>
</tr>
<tr>
<td>Total</td>
<td>72</td>
<td>37</td>
<td>26/46</td>
<td>26/59 (44)</td>
<td>30/54 (56)</td>
<td>10</td>
<td>51</td>
<td>11</td>
</tr>
</tbody>
</table>

Note: UST, ultrastructural subtype; MA, median age; F/M, female/male; KA, karyotype abnormality; CT, case tested; CR, complete remission; TC, treated cases.

TEM Ultrastructural Classification

On the basis of ultrastructural criteria, four subtypes of M5—TMB, AMB, APM, and TPM—were identified. The numbers of cases of these subtypes and their composition in terms of being M5a, b, or u are given in Table 2. No significant difference existed in age and sex between any two of the four ultrastructural subtypes, as well as between MB and PM types.

Cytochemistry

Cytochemical data were available for all cases (Table 3). Positive indices of ACP, PAS, POX, CE, and SBB mostly increased from TMB to TPM subtype, though there was no statistical difference between them. The NBE index for TPM and APM was higher than for TMB and AMB statistically and respectively ($p < .05$). The NAE index of APM subtype was higher than for AMB subtype statistically ($p < .005$). Indices of PAS, POX, CE, SBB, NAE, and NBE for MB type were higher than for PM type and there was significant difference between them ($p < .05$).

Immunophenotyping

For the 69 patients tested, the numbers and percentages of cases positive for the relevant MoAbs in the four subtypes are listed in Table 4. CD33, HLA-DR, CD13, and CD117 were highly expressed in the four subtypes and there was no statistical difference between them. CD34, CD7, and CD19 generally decreased from TMB to TPM subtypes. CD34 was
higher in MB than PM type but without significant difference, while CD7 was higher in MB than PM type statistically \( (p < .05) \). CD14, CD56, and CD64 increased from TMB to TPM subtypes. For CD14, the differences between TMB and TPM subtypes and between MB and PM types were statistically significant \( (p < .05) \). CD64 was significantly decreased in TMB compared with AMB, APM, and TPM subtypes, and it was decreased in TPM compared with AMB and APM subtypes respectively and statistically \( (p < .05) \). Additionally, the MB and PM types were significantly different for CD56 \( (p < .05) \).

**DISCUSSION**

M5 is conventionally subdivided into M5a and M5b according to the numbers of monoblasts or promonocytes in the monocytic series by light microscopy in the FAB and WHO protocols, in which the monoblast is defined as having round nuclei, finely dispersed chromatin, prominent nucleoli, and abundant basophilic cytoplasm, while the promonocyte has irregular nuclei and less intensely basophilic cytoplasm [2]. Though the morphological identification by light microscopy is a quick, simple, and cheap method that is universally accepted, some M5 patients are still difficult to categorize as M5a or M5b. For example, the blasts in some M5 patients do not show the typical morphological features of monoblasts or promonocytes as in the FAB description. In addition, there is interobserver inconsistency among some FAB M5 patients. In the present study, 11 cases (15.3%) were unclassified on the basis of strikingly contradictory clinical opinions. Such clinical inconsistencies may be responsible for the difficulties reported in the literature in distinguishing M5a and M5b.

In this study, we have succeeded in classifying M5 on the basis of the ultrastructurally determined predominant monocytic blasts, of which we have identified four kinds—TMB, AMB, APM, and TPM subtypes. The TMB subtypes were poorly differentiated, while the TPM subtypes were well-differentiated: AMB and APM showed an intermediate level of differentiation. These differences in differentiation are based on features such as larger size of AMB compared with TMB; numerous vacuoles and granules in TPM and APM compared with TMB and AMB; and larger nuclei and nucleoli in AMB and APM compared with TMB and TPM. These characteristics have illustrated consecutive differentiation stages, helping to make more precise definitions of monoblasts and promonocytes and refine the light microscopy criteria in M5. Therefore, this subtyping system may reveal relationships between the morphology and the clinic

### Table 3. Cytochemistry in four ultrastructural subtypes of AML-M5: positive indices.

<table>
<thead>
<tr>
<th>UST</th>
<th>ACP</th>
<th>PAS</th>
<th>POX</th>
<th>CE</th>
<th>SBB</th>
<th>NAE</th>
<th>NBE</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMB</td>
<td>103 ± 70</td>
<td>108 ± 24</td>
<td>45 ± 56</td>
<td>14 ± 21</td>
<td>59 ± 61</td>
<td>89 ± 61</td>
<td>10 ± 11</td>
</tr>
<tr>
<td>AMB</td>
<td>100 ± 65</td>
<td>123 ± 37</td>
<td>65 ± 62</td>
<td>40 ± 60</td>
<td>90 ± 70</td>
<td>62 ± 62</td>
<td>23 ± 23</td>
</tr>
<tr>
<td>APM</td>
<td>119 ± 64</td>
<td>153 ± 52</td>
<td>115 ± 112</td>
<td>77 ± 107</td>
<td>138 ± 115</td>
<td>151 ± 121</td>
<td>136 ± 147</td>
</tr>
<tr>
<td>TPM</td>
<td>122 ± 43</td>
<td>136 ± 41</td>
<td>103 ± 82</td>
<td>69 ± 61</td>
<td>136 ± 80</td>
<td>114 ± 80</td>
<td>98 ± 95</td>
</tr>
</tbody>
</table>

Note. MB, TMB + AMB; PM, TPM + APM; ★, compared with TMB, \( p < .05 \); ●, compared with AMB, \( p < .05 \); ▲, compared with MB, \( p < .05 \).

### Table 4. Flow cytometry in the four ultrastructural subtypes of AML-M5: positive cases (%).

<table>
<thead>
<tr>
<th>UST</th>
<th>TC</th>
<th>CD13</th>
<th>CD33</th>
<th>CD117</th>
<th>DR</th>
<th>CD19</th>
<th>CD34</th>
<th>CD7</th>
<th>CD14</th>
<th>CD56</th>
<th>CD64</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMB</td>
<td>12</td>
<td>11 (92)</td>
<td>11 (91.7)</td>
<td>12 (100)</td>
<td>11 (92)</td>
<td>3 (25)</td>
<td>11 (92)</td>
<td>6 (50)</td>
<td>1 (8.3)</td>
<td>3 (25)</td>
<td>2 (16.7)</td>
</tr>
<tr>
<td>AMB</td>
<td>20</td>
<td>16 (80)</td>
<td>19 (95)</td>
<td>17 (85)</td>
<td>20 (100)</td>
<td>3 (15)</td>
<td>16 (80)</td>
<td>10 (50)</td>
<td>5 (25)</td>
<td>6 (30)</td>
<td>13 (65)</td>
</tr>
<tr>
<td>APM</td>
<td>14</td>
<td>13 (93)</td>
<td>14 (100)</td>
<td>11 (78.6)</td>
<td>14 (100)</td>
<td>2 (14.3)</td>
<td>8 (57)</td>
<td>2 (14.3)</td>
<td>5 (35.7)</td>
<td>6 (42.9)</td>
<td>9 (64.3)</td>
</tr>
<tr>
<td>TPM</td>
<td>23</td>
<td>23 (100)</td>
<td>21 (91.3)</td>
<td>17 (73.9)</td>
<td>18 (78.2)</td>
<td>2 (8.7)</td>
<td>14 (60.9)</td>
<td>5 (21.7)</td>
<td>13 (56.5)</td>
<td>13 (56.5)</td>
<td>9 (26.6)</td>
</tr>
<tr>
<td>MB</td>
<td>32</td>
<td>27 (84.4)</td>
<td>30 (93.8)</td>
<td>29 (90.6)</td>
<td>31 (96.9)</td>
<td>6 (18.7)</td>
<td>27 (84.4)</td>
<td>16 (50)</td>
<td>6 (18.8)</td>
<td>9 (28.1)</td>
<td>15 (46.9)</td>
</tr>
<tr>
<td>PM</td>
<td>37</td>
<td>36 (97.3)</td>
<td>35 (94.6)</td>
<td>28 (75.7)</td>
<td>32 (86.5)</td>
<td>4 (10.8)</td>
<td>22 (54)</td>
<td>7 (18.9)</td>
<td>18 (48.6)</td>
<td>19 (51.4)</td>
<td>28 (75.7)</td>
</tr>
</tbody>
</table>

TC, tested cases; ★, compared with TMB, \( p < .05 \); ●, compared with TPM, \( p < .05 \); ▲, compared with MB, \( p < .05 \).
significances such as karyotyping, CR, cytochemistry, and immunophenotyping.

Of 59 available cases, karyotype abnormality showed no significant difference between any two of the four subtypes or between MB and PM types, respectively. In 54 available cases, there was an increasing tendency of CR for TMB to TPM. Patients of MB type had poorer CR than those of PM type, demonstrating the correlation between higher ultrastructural differentiation and better CR rates. Our ultrastructural classification therefore shows that there is a difference prognostically between M5a and M5b, whereas other workers have sometimes found a difference and sometimes not [13].

Cytochemically, although the indices for ACP, PAS, POX, CE, and SBB increased from TMB to TPM generally, they were not statistically different among the four subtypes. NAE and NBE indices also increased from TMB to TPM subtype and the NBE index was significantly higher in TPM and APM than in TMB and AMB subtypes, respectively. These data confirmed that NBE was more specific for monocytic differentiation but less sensitive than NAE [14]. With the exception of ACP, the indices of PAS, POX, CE, SBB, NAE, and NBE in the PM type were statistically higher than in the MB type, indicating that the enzymograms expression correlated with ultrastructural differentiation (Figure 4).

Immunophenotypically, all four subtypes showed strong positivity for the common myeloid markers, consistent with the literature, and showed no correlation with differentiation [15]. There was a gradual decrease in CD34 positivity from TMB to TPM subtype and a statistical difference between MB and PM types. Patients of MB type were more frequently positive for
CD7 than PM type statistically, suggesting that CD34 and CD7 were more frequently expressed in the poorly differentiated monocytic series as in other AML and may be associated with worse prognosis [16].

CD14 and CD64 are specific antigens for monocytes, although they are not completely sensitive in M5 patients [17]. Our data showed cases positive for these antigens increasing from TMB to TPM subtypes generally, and significant differences between the four subtypes. The data demonstrated that these antigens were usually expressed on well-differentiated monocytic blasts in M5. CD56 is a natural killer (NK) cell marker identified in approximately 15–20% of AML, and is associated with monocytic morphology [18]. In our study, the percentage of cases positive for CD56 also increased from TMB to TPM subtypes with a statistically difference between MB and PM types. Therefore, the ultrastructural subtypes were correlated with the antigens expression immunophenotypically (Figure 5 and 6).

CONCLUSION

Cells of the monocytic series exhibited a number of ultrastructural features in different M5 patients, enabling them to be divided into two broad groups (types) — monoblastic and promonocytic — based on features such as cytoplasmic volume, development of Golgi apparatus, and numbers of vesicles and granules. Monoblast-predominant M5 patients expressed weaker monocytic enzymograms and specific antigens, CD14 and CD64, compared with promonocyte-predominant M5 patients. CD34 and CD7 were more frequently expressed in the monoblast-predominant patients. Monoblast-predominant M5 patients had poorer CR than promonocyte-predominant patients. Therefore, the ultrastructural subclassification on basis of the predominant blast type differs from and improves on the light microscopical criteria for distinguishing monoblasts and promonocytes and has clinical significance.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

REFERENCES